Press Release

Illumina to Webcast Live Presentation at Upcoming Investment Conferences in June

SAN DIEGO--(BUSINESS WIRE)--May 21, 2015-- Illumina, Inc. (NASDAQ:ILMN) today announced that it will webcast the Company’s presentation at two upcoming investment conferences.

Illumina will webcast its presentation at the Bank of America Merrill Lynch 2015 Global Technology Conference in San Francisco, California, on June 3, 2015. The live webcast is scheduled to begin at 8:30 AM PT and will feature an overview of the company by Francis deSouza, President, followed by a question and answer session.

Illumina will also webcast its presentation at the Goldman Sachs 36th Global Healthcare Conference in Rancho Palos Verdes, California, on June 10, 2015. The live webcast is scheduled to begin at 10:00 AM PT and will feature a brief overview of the company by Marc Stapley, Senior Vice President and Chief Financial Officer, followed by a question and answer session.

The webcasts can be accessed in the Investor Relations section of Illumina's web site under the "Company" tab at www.illumina.com.

About Illumina

Illumina is transforming human health as the global leader in sequencing and array-based technologies. The company serves customers in a broad range of markets, enabling the adoption of genomic solutions in research and clinical settings. To learn how Illumina is unlocking the power of the genome, visit www.illumina.com and follow @illumina.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com

Recent Articles

Studying epigenetics to avoid unwanted effects of blood transfusions
Studying epigenetics to avoid unwanted effects of blood transfusions
Illumina showcases innovations at the 7th China International Import Expo
Video: Illumina showcases innovations at the 7th China International Import Expo
Programs around the globe bring newborn screening into the Genome Era
Programs around the globe bring newborn screening into the Genome Era